HIV

The biggest barriers to stopping the transmission of HIV are both the large population of infected people not receiving treatment and the lack of pre-exposure prophylaxis for high-risk individuals, said Thomas C. Quinn, MD, director of the Johns Hopkins Center for Global Health.

A Kaiser Family Foundation web briefing navigated the HIV/AIDS funding landscape, taking a look at trends over time, the latest data, and what we might expect in the future.

The National Cancer Institute (NCI) is sponsoring an ongoing clinical trial that evaluates pembrolizumab in people with HIV who have relapsed or refractory cancer and are also taking antiretroviral therapy. People with HIV are often excluded from participating in clinical trials of new cancer treatments because of concerns that treatments may be unsafe for them.

A woman gives birth after receivng a uterine transplant for the first time in the US; a once-monthly treatment for patients with poioid addiction gains FDA approval; and LA public health officials launch an initiative to reduce the annual number HIV infections.